Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms.
- Author:
Peng YUAN
1
;
Xiao-ping MIAO
;
Xue-mei ZHANG
;
Zhong-hua WANG
;
Wen TAN
;
Xiang-ru ZHANG
;
Yan SUN
;
Bing-he XU
;
Dong-xin LIN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Agents; therapeutic use; Carboplatin; administration & dosage; Carcinoma, Non-Small-Cell Lung; drug therapy; genetics; pathology; Cisplatin; administration & dosage; DNA-Binding Proteins; genetics; Exons; Female; Genotype; Humans; Lung Neoplasms; drug therapy; genetics; pathology; Male; Middle Aged; Neoplasm Staging; Nuclear Proteins; genetics; Paclitaxel; administration & dosage; Polymorphism, Genetic; Tumor Protein p73; Tumor Suppressor Protein p53; genetics; Tumor Suppressor Proteins; genetics
- From: Chinese Journal of Oncology 2006;28(2):107-110
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEIt has been proposed that genetic polymorphisms in apoptosis-related genes might be associated with sensitivity of cancer cells to platinum-based chemotherapy. This study examined the relationship between p53 and p73 genetic polymorphisms and the response to platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
METHODSA total of 165 patients with advanced NSCLC treated with platinum-based chemotherapy were genotyped for the p53 codon 72 Pro-->Arg and p73 exon 2 G4C14-->A4T14 polymorphisms using PCR-RFLP and ARMS-PCR assays. Clinical response to the chemotherapy was obtained after 2 to 3 cycles. The adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using unconditional logistic regression model. All statistical tests were two-sided.
RESULTSThe p53 Pro allele carriers had higher response rate than non-carriers (OR = 2.46; 95% CI = 1.11 - 5.45). A higher response rate was also observed for the p73 G4C14/A4T14 or A4T14/A4T14 genotype, compared with the G4C14/G4C14 genotype (OR = 2.22; 95% CI = 1.14 - 4.30). When these two polymorphisms were combined to be analyzed, it was found that the response rate in those carrying the wild-type genotypes at both genes was only 7.7%, whereas the response rates in patients carrying 1, 2, or more than 2 variant alleles of p53 and p73 were 34.8%, 42.2% and 40.7%, respectively.
CONCLUSIONThose results suggest that p53 and p73 polymorphisms may be associated with clinical responsiveness to platinum-based chemotherapy in advanced NSCLC.
